Price$29.11+0.61 (+2.12%)
01:30 PM07:45 PM
News · 26 weeks57+67%
2025-12-142026-06-07
Mix3290d
- Insider16(50%)
- Other8(25%)
- SEC Filings6(19%)
- Earnings2(6%)
Latest news
25 items- INSIDERDirector Desai Antal Rohit was granted 3,315 shares, increasing direct ownership by 9% to 38,467 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERDirector Dodrill Amy M. was granted 3,315 shares, increasing direct ownership by 43% to 10,941 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERDirector Garrett Mary was granted 3,315 shares, increasing direct ownership by 23% to 17,700 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERDirector Harris Taylor C. was granted 3,315 shares, increasing direct ownership by 3% to 102,491 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERDirector Little Elisabeth Sandoval was granted 3,315 shares, increasing direct ownership by 26% to 15,876 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERDirector Moll Frederic H was granted 3,315 shares, increasing direct ownership by 0.38% to 866,474 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERDirector Prescott Thomas M was granted 3,315 shares, increasing direct ownership by 85% to 7,211 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDERDirector Puckett Dan was granted 3,315 shares, increasing direct ownership by 61% to 8,791 units (SEC Form 4)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- SECPROCEPT BioRobotics Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)
- INSIDEREVP, CLO, CORP. SEC. Nouri Alaleh sold $8,117 worth of shares (285 units at $28.48), decreasing direct ownership by 0.27% to 105,069 units (SEC Form 4) (withholding tax)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDEREVP, CFO Waters Kevin sold $10,167 worth of shares (357 units at $28.48), decreasing direct ownership by 0.24% to 151,201 units (SEC Form 4) (tax withholding)4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- INSIDEREVP, Chief Technology Officer Templin Barry L sold $10,195 worth of shares (358 units at $28.48), decreasing direct ownership by 0.52% to 68,953 units (SEC Form 4) to satisfy withholding obligation4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- SECSEC Form SD filed by PROCEPT BioRobotics CorporationSD - PROCEPT BioRobotics Corp (0001588978) (Filer)
- PRPROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE ApprovalSAN JOSE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the randomized WATER IV study evaluating Aquablation® therapy versus radical prostatectomy, and FDA Investigational Device Exemption (IDE) approval for a second randomized protocol evaluating Aquablation therapy versus active surveillance. The first randomized WATER IV study (WATER IV RP) fully enrolled 280 planned patients and is the only FDA randomized study comparing Aquablation therapy to radical prostatectomy, the established surgical standard of care. Based on current timelines, the Company e
- SECAmendment: SEC Form SCHEDULE 13G/A filed by PROCEPT BioRobotics CorporationSCHEDULE 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
- PRAUA Guidelines Strengthen Recommendation for Aquablation® TherapySAN JOSE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (NASDAQ:PRCT) today highlighted the latest update to the American Urological Association (AUA) Guidelines for the management of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH), which strengthen the recommendation for Aquablation therapy (Robotic Waterjet Treatment) as a surgical treatment option for men with prostate volumes 30–80 mL. The guidelines also recognize that Aquablation therapy may be offered in larger prostates (80–150 mL), expanding its use across a broader patient population. The update reflects the maturity of the clinical evidence supporting Aquablation therapy, inc
- INSIDERNew insider Templin Barry L claimed ownership of 125,768 shares (SEC Form 3)3 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- SECSEC Form 10-Q filed by PROCEPT BioRobotics Corporation10-Q - PROCEPT BioRobotics Corp (0001588978) (Filer)
- PRPROCEPT BioRobotics® to Attend Three Upcoming Investor Conferences in May & JuneSAN JOSE, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of management will present at three upcoming investor conferences in May and June. 2026 Bank of America Health Care Conference Location – Las Vegas, NVFireside Chat – Tuesday, May 12 at 3:40pm PT / 6:40pm ET 46th Annual William Blair Growth Stock Conference Location – Chicago, ILPresentation – Tuesday, June 2 at 12pm CT / 1pm ET 2026 Truist Med-Tech Conference Location – Boston, MAFireside Chat – Tuesday, June 16 at 1:40am ET A live webcast
- SECPROCEPT BioRobotics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)
- PRPROCEPT BioRobotics Reports First Quarter 2026 Financial ResultsSAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2026. "Over the past six months, we have taken decisive actions to reset the organization by sharpening our focus on operational excellence, accountability, and commercial discipline, and our first quarter results reflect the early impact of that work," said Larry Wood, Chief Executive Officer. "We delivered $83.1 million in revenue, driven by strong U.S. system sales and improved pricing.
- INSIDERNew insider Sharma Pooja claimed ownership of 87,559 shares (SEC Form 3)3 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
- SECSEC Form DEFA14A filed by PROCEPT BioRobotics CorporationDEFA14A - PROCEPT BioRobotics Corp (0001588978) (Filer)
- SECSEC Form DEF 14A filed by PROCEPT BioRobotics CorporationDEF 14A - PROCEPT BioRobotics Corp (0001588978) (Filer)
- PRPROCEPT BioRobotics® to Report First Quarter 2026 Financial Results on April 29, 2026SAN JOSE, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2026 after market close on Wednesday, April 29, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/rdtftqik/ Dial-in registration for sell-side research
PRCT FAQ
7 questionsWhat does PROCEPT BioRobotics Corporation do?
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.Where does PRCT stock trade?
PROCEPT BioRobotics Corporation (PRCT) is listed on NASDAQ.What sector and industry is PRCT in?
PROCEPT BioRobotics Corporation operates in the Health Care sector, Medical/Dental Instruments industry.When did PROCEPT BioRobotics Corporation go public?
PROCEPT BioRobotics Corporation (PRCT) completed its IPO in 2021.What are analysts saying about PRCT?
PROCEPT BioRobotics Corporation has had 8 recent analyst actions on file. The most recent action was from Robert W. Baird: Neutral with a $3000.00 price target on 2026-03-06. Recent price targets range from $2000.00 to $3800.00.What companies are similar to PRCT?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare PRCT side-by-side with any of them on Quantisnow.How can I track PRCT on Quantisnow?
Quantisnow aggregates PROCEPT BioRobotics Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRCT to receive live email and push alerts on every new disclosure.